HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Protective effects of the angiotensin II type 1 (AT1) receptor blockade in low-renin deoxycorticosterone acetate (DOCA)-treated spontaneously hypertensive rats.

Abstract
The present study evaluates the participation of oxidative stress, tissue angiotensin II (Ang II) and endothelin (ET) in the effects of losartan on blood pressure (BP), ventricular hypertrophy and renal injury in spontaneously hypertensive rats (SHRs), and explores how these effects are modified when spontaneous hypertension is transformed in a low-renin model by the administration of deoxycorticosterone acetate (DOCA). The following groups were used: SHR-control, SHR+DOCA, SHR+losartan and SHR+DOCA+losartan. Tail systolic BP was measured once a week. After 9 weeks of treatment, direct BP and metabolic, morphological, biochemical and renal variables were measured. DOCA administration to SHRs produced an increase in BP, ventricular hypertrophy, renal weight, proteinuria, renal histopathological lesions, urinary excretion of isoprostane F2alpha and ET levels in the renal cortex. Losartan reduced BP, plasma malondialdehyde levels, urinary excretion of isoprostane F2alpha, renal Ang II and renal and urinary levels of ET in the SHR and DOCA-treated SHR groups. Losartan increased plasma nitrite/nitrate in SHRs, but not in low-renin DOCA-treated SHRs. Losartan reduced ventricular hypertrophy and ventricular Ang II in SHRs, but not in DOCA-treated SHRs. Losartan significantly decreased proteinuria and renal injury in DOCA-treated SHRs. We conclude that (i) the DOCA-induced aggravation of hypertension, ventricular hypertrophy and renal injury in SHRs is accompanied by augmented oxidative stress and increased levels of ET in the renal cortex, which could contribute to their development; and (ii) losartan reduced oxidative stress and renal Ang II and ET in SHRs and DOCA-treated SHRs, which might contribute to its antihypertensive and renoprotective effects, regardless of renin status.
AuthorsVirginia Chamorro, Rosemary Wangensteen, Juan Sainz, Juan Duarte, Francisco O'Valle, Antonio Osuna, Félix Vargas
JournalClinical science (London, England : 1979) (Clin Sci (Lond)) Vol. 106 Issue 3 Pg. 251-9 (Mar 2004) ISSN: 0143-5221 [Print] England
PMID14521506 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Angiotensin II Type 1 Receptor Blockers
  • Antihypertensive Agents
  • Endothelins
  • Isoprostanes
  • isoprostane F2alpha III
  • Angiotensin II
  • Desoxycorticosterone
  • Malondialdehyde
  • Renin
  • Losartan
Topics
  • Angiotensin II (metabolism)
  • Angiotensin II Type 1 Receptor Blockers
  • Animals
  • Antihypertensive Agents (therapeutic use)
  • Cardiomegaly (metabolism)
  • Desoxycorticosterone
  • Endothelins (analysis, metabolism)
  • Hypertension (drug therapy, metabolism)
  • Isoprostanes (urine)
  • Kidney (metabolism)
  • Losartan (therapeutic use)
  • Male
  • Malondialdehyde (blood)
  • Proteinuria (metabolism)
  • Rats
  • Rats, Inbred SHR
  • Renin (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: